Onyx Pharmaceuticals Receives “Buy” Rating from Jefferies Group (ONXX)
Onyx Pharmaceuticals (NASDAQ: ONXX)‘s stock had its “buy” rating reiterated by equities research analysts at Jefferies Group in a research note issued to investors on Monday. They currently have a $96.00 price target on the stock.
ONXX has been the subject of a number of other recent research reports. Analysts at Zacks downgraded shares of Onyx Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note to investors on Friday. They now have a $88.00 price target on the stock. Separately, analysts at JMP Securities raised their price target on shares of Onyx Pharmaceuticals from $100.00 to $102.00 in a research note to investors on Friday, February 22nd. Finally, analysts at Bank of America reiterated a “buy” rating on shares of Onyx Pharmaceuticals in a research note to investors on Friday, February 22nd. They now have a $100.00 price target on the stock, up previously from $99.00.
Sixteen equities research analysts have rated the stock with a buy rating, two have given an overweight rating, and four have assigned a hold rating to the company’s stock. The company has a consensus rating of “buy” and an average price target of $100.88.
Shares of Onyx Pharmaceuticals opened at 85.65 on Monday. Onyx Pharmaceuticals has a 52 week low of $36.53 and a 52 week high of $93.18. The stock’s 50-day moving average is currently $76.80. The company’s market cap is $6.167 billion.
Onyx Pharmaceuticals last issued its quarterly earnings data on Thursday, February 21st. The company reported ($0.36) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.76) by $0.40. The company had revenue of $127.90 million for the quarter, compared to the consensus estimate of $113.17 million. During the same quarter in the prior year, the company posted $1.50 earnings per share. The company’s quarterly revenue was down 46.0% on a year-over-year basis. On average, analysts predict that Onyx Pharmaceuticals will post $-2.41 earnings per share for the current fiscal year.
Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company. The Company is developing therapies that target the molecular mechanisms that cause cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.